NRXS vs. SURG, ICAD, APT, TMDIF, ECOR, TELA, APYX, BDMD, DXR, and SPAI
Should you be buying NeurAxis stock or one of its competitors? The main competitors of NeurAxis include SurgePays (SURG), iCAD (ICAD), Alpha Pro Tech (APT), Titan Medical (TMDIF), electroCore (ECOR), TELA Bio (TELA), Apyx Medical (APYX), Baird Medical Investment (BDMD), Daxor (DXR), and Safe Pro Group Inc. Common Stock (SPAI). These companies are all part of the "medical equipment" industry.
NeurAxis vs.
SurgePays (NASDAQ:SURG) and NeurAxis (NASDAQ:NRXS) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
SurgePays has a net margin of -27.39% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat SurgePays' return on equity.
In the previous week, SurgePays had 2 more articles in the media than NeurAxis. MarketBeat recorded 2 mentions for SurgePays and 0 mentions for NeurAxis. SurgePays' average media sentiment score of 0.47 beat NeurAxis' score of 0.00 indicating that SurgePays is being referred to more favorably in the media.
SurgePays currently has a consensus target price of $8.50, indicating a potential upside of 241.37%. Given SurgePays' stronger consensus rating and higher possible upside, research analysts clearly believe SurgePays is more favorable than NeurAxis.
SurgePays has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.
SurgePays received 169 more outperform votes than NeurAxis when rated by MarketBeat users. However, 100.00% of users gave NeurAxis an outperform vote while only 69.11% of users gave SurgePays an outperform vote.
6.9% of SurgePays shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 29.4% of SurgePays shares are owned by company insiders. Comparatively, 15.2% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
SurgePays has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.46, suggesting that its stock price is 246% more volatile than the S&P 500.
Summary
SurgePays beats NeurAxis on 11 of the 18 factors compared between the two stocks.
Get NeurAxis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeurAxis Competitors List
Related Companies and Tools
This page (NASDAQ:NRXS) was last updated on 4/18/2025 by MarketBeat.com Staff
Buy NRXS Stock Free NRXS Stock Alerts